#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Ewing's sarcoma recurrent Insulinoma Soft tissue sarcoma Glioma Subarachnoid haemorrhage Retinitis pigmentosa Waldenstrom's macroglobulinaemia refractory Diffuse large B-cell lymphoma Pulmonary alveolar haemorrhage Bulbospinal muscular atrophy congenital Huntington's disease Pulmonary hypertension Cholangitis sclerosing Epileptic encephalopathy Glioblastoma multiforme More trials…

    Learn about Rare Diseases

    Waldenstrom’s macroglobulinaemia refractory – Trials in Disease Cholangitis sclerosing – Treatment Alveolar rhabdomyosarcoma – Diagnostics Prader-Willi syndrome Alport’s syndrome Activated PI3 kinase delta syndrome – Basic Information Pulmonary fibrosis – Treatment Retinoblastoma – Basic Information Haemophilia B without inhibitors – Treatment Hypereosinophilic syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sasanlimab AB521 Murcidencel Carmustine Pomalidomide Calcitriol BW-20805 Mosunetuzumab Tanimilast Tipiracil Abc-31-116 Atropine Sulfate Monohydrate Norepinephrine Sot102 Parsaclisib Hydrochloride Atrasentan Hydrochloride Atuliflapon Mk-6194 Brimonidine Acp-204 Tartrate More therapies…

    Learn about Your Condition

    Muscle hypertrophy Embolic stroke Oesophagectomy Carcinoid syndrome Dermatitis Rhabdoid tumour Exfoliation glaucoma Pleural mesothelioma malignant Hypercholesterolaemia Pseudomyxoma peritonei Pancreatitis relapsing Habitual abortion Rectal neoplasm Nicotine dependence Arrhythmia supraventricular More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Nzsbrxhdk Kwzje 9bo Dfwtiohww 4pken Hytxyif

Want to learn more about this study or check if you can participate? Contact us.

  • Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

    Recruiting

    2 1
    Bulgaria Denmark France Germany Greece Hungary +4

  • A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

    Recruiting

    3 1 1
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Czechia Denmark Germany Greece Hungary Poland +1

  • Efficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial

    Recruiting

    4 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • LUNSEKIMIG
    Belgium Denmark Estonia Finland France Germany +7

  • Efficacy and Safety of Inhaled Glycopyrronium Bromide Added to Budesonide and Formoterol Fumarate in Children 4‑12 Years with Asthma (Placebo‑Controlled)

    Recruiting

    2 1
    Investigated Drugs:
    • Formoterol Fumarate
    • Glycopyrronium Bromide
    • Budesonide
    Czechia Hungary Poland

  • Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    • Gastric cancer
    Investigated Drugs:
    • Azd0901
    • Zolbetuximab
    • Capecitabine
    Belgium France Germany Hungary Italy The Netherlands +2

  • Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Emicizumab
    • Ro7589655
    Austria Belgium Denmark France Germany Hungary +5

  • Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

    Recruiting

    3 1 1
    Investigated Drugs:
    • Indacaterol Acetate
    • Mometasone Furoate
    • Salbutamol
    France Germany Hungary Poland Romania Slovakia +1

  • Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

    Recruiting

    3 1
    Investigated Diseases:
    • Systemic lupus erythematosus
    Investigated Drugs:
    • Nipocalimab
    Bulgaria Czechia Denmark Finland France Germany +9

  • Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Asciminib Hydrochloride
    France Germany Greece Hungary Italy The Netherlands +2

  • Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1 1
    Investigated Diseases:
    • Overweight
    • Type 2 diabetes mellitus
    • Obesity
    Investigated Drugs:
    • Semaglutide
    Bulgaria Croatia Germany Hungary Poland Portugal +1
1 2 3 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!